Insulin resistance and aging: a cause or a protective response
The plaintiffs filed a motion in December 2023 to consolidate Ozempic lawsuits into a class-action lawsuit or multidistrict litigation (MDL) which occurred in early February, creating the official Ozempic lawsuit MDL 3094
In the same week that Pfizer decided to discontinue the development of danuglipron, an oral, small-molecule GLP-1 receptor agonist aimed at chronic weight management Lilly report a successful Phase 3 trial with Orforglipron, lowering A1C and body weight BREAKING: Lillys oral GLP-1, orforglipron, hits its primary endpoint in the Phase 3 ACHIEVE-1 trial for type 2 diabetes
Instead of gambling $3,0005,000/month on marketing with uncertain results, Klarity Health uses a pay-per-appointment model (similar to Zocdoc) where providers pay a standard listing fee per new patient lead
Adults with a BMI of 30 or higher or a BMI of 27 or higher with a weight-related condition may be eligible for semaglutide as a weight management tool
